Monday, October 5, 2020 Daily Archives

Cell Culture Media Manufacturing, Outsourcing and the Pandemic: An Essential Toolkit

This webcast features: Chad Schwartz, Senior Global Product Manager for Proprietary Cell Culture Media Formulations, and  Eric Nalbach, Director of Product Management, Bioproduction, Cell Culture Media, Thermo Fisher Scientific The COVID-19 pandemic has had an unprecedented impact across the bioproduction industry, from supply chains to working practices. As organizations adapt to such changes, they have already experienced huge shifts in how the industry works. Those working in both research and manufacturing feel an obligation to employ all available resources to…

Sartorius set to acquire BIA Separations for $423m

Sartorius Stedim Biotech has announced plans to buy Slovenian purification tech firm BIA Separations for €360 million ($423 million). The deal will see Sartorius pay €240 million upfront and €120 million in shares. The firm will also pay tranches of earn-out payments over the next five years. The transaction is expected to complete before the end of the year. Ajdovščina, Slovenia-headquartered BIA develops and manufactures products for purification and analysis of large biomolecules, including viruses, plasmids and mRNA. Sartorius CEO…

BMS to buy MyoKardia, adding heart disease drug for $13.1bn

BMS Myers Squibb (BMS) is bolstering its cardiovascular drug lineup with a $13.1 billion deal to acquire MyoKardia, a company whose experimental therapy for a rare type of heart disease is on track for an FDA submission and is projected to become a blockbuster seller. According to financial terms announced Monday, BMS has agreed to pay $225 cash for each share of MyoKardia, a 61 percent premium to the Brisbane, Califrnia-based company’s closing stock price on Friday. Shares of MyoKardia opened at…

Astrea continues acquisition path picking up purification firm Nanopareil

A transformative year for Astrea Bioseparations has culminated in a second acquisition in a month. Philip Vanek, CTO of parent company Gamma Biosciences, talks to us about the deal, the company, and the changing bioprocess landscape. In November 2019, investment firm KKR announced its intentions to buy Prometic Bioseparations from Liminal BioSciences. In January, the deal closed with renamed Astrea Bioseparations becoming the first company in KKR’s $200 million Gamma Biosciences portfolio of life sciences tools subsidiaries. Since then, the firm…